<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><title>THE "NEW" PROSTATE CANCER INFOLINK</title><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:Georgia;
panose-1:2 4 5 2 5 4 5 2 3 3;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:24.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-family:"Cambria","serif";
color:#365F91;
font-weight:bold;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:644047881;
mso-list-template-ids:-846932518;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
ol
{margin-bottom:0cm;}
ul
{margin-bottom:0cm;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>See below for several interesting articles.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Be cautioned that the 2<sup>nd</sup> article has a rather graphic picture.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Take care,<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> noreply+feedproxy@google.com [mailto:noreply+feedproxy@google.com] <br><b>Sent:</b> July 5, 2018 9:05 PM<br><b>To:</b> glen46nor@gmail.com<br><b>Subject:</b> The Prostate Cancer InfoLink<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><div style='margin-left:24.0pt;margin-right:24.0pt' id=emailbody><table class=MsoNormalTable border=0 cellpadding=0 width="100%" style='width:100.0%'><tr><td width="99%" valign=top style='width:99.0%;padding:0cm 0cm 0cm 0cm'><h1 style='margin:0cm;margin-bottom:.0001pt'><a href="https://prostatecancerinfolink.net" title="(https://prostatecancerinfolink.net)"><span style='font-size:16.5pt;font-family:"Arial","sans-serif";color:#888888;font-weight:normal;text-decoration:none'>The Prostate Cancer InfoLink</span></a> <o:p></o:p></h1></td><td width="1%" style='width:1.0%;padding:0cm 0cm 0cm 0cm'></td></tr></table><div class=MsoNormal align=center style='text-align:center;line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:black'><hr size=2 width="100%" align=center></span></div><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:black'><ul type=disc id=summarylist><li class=MsoNormal style='color:black;mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:140%;mso-list:l0 level1 lfo1'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif"'><a href="#1"><b><span style='color:#000099;text-decoration:none'>5-year follow-up after focal therapy with HIFU for localized prostate cancer</span></b></a> <o:p></o:p></span></li><li class=MsoNormal style='color:black;mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:140%;mso-list:l0 level1 lfo1'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif"'><a href="#2"><b><span style='color:#000099;text-decoration:none'>A rare case of cutaneous, metastatic prostate cancer</span></b></a> <o:p></o:p></span></li><li class=MsoNormal style='color:black;mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:140%;mso-list:l0 level1 lfo1'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif"'><a href="#3"><b><span style='color:#000099;text-decoration:none'>Prediction of potentially lethal forms of prostate cancer</span></b></a> <o:p></o:p></span></li></ul></span><table class=MsoNormalTable border=0 cellpadding=0 id=itemcontentlist><tr><td style='padding:.75pt .75pt .75pt .75pt'><p style='mso-margin-top-alt:12.0pt;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:16.8pt'><a name=1></a><a href="http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/P3uBMlWBKIw/?utm_source=feedburner&utm_medium=email"><b><span style='font-size:13.5pt;font-family:"Arial","sans-serif";color:#000099;text-decoration:none'>5-year follow-up after focal therapy with HIFU for localized prostate cancer</span></b></a> <o:p></o:p></p><p style='mso-margin-top-alt:6.75pt;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:#555555'>Posted: 05 Jul 2018 10:14 AM PDT<o:p></o:p></span></p><div><p class=MsoNormal style='line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:black'>A new paper from the Emberton-Ahmed group in the UK has reported 5-year follow-up data from a cohort of > 600 patients with clinically significant, localized prostate cancer, all treated with focal forms of high-intensity focused ultrasound (HIFU). The entire text of this new paper by Guillaumier et al. is available on line in European […]<o:p></o:p></span></p></div></td></tr><tr><td style='padding:.75pt .75pt .75pt .75pt'><p style='mso-margin-top-alt:12.0pt;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:16.8pt'><a name=2></a><a href="http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/nK3OYATWCIg/?utm_source=feedburner&utm_medium=email"><b><span style='font-size:13.5pt;font-family:"Arial","sans-serif";color:#000099;text-decoration:none'>A rare case of cutaneous, metastatic prostate cancer</span></b></a> <o:p></o:p></p><p style='mso-margin-top-alt:6.75pt;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:#555555'>Posted: 05 Jul 2018 05:42 AM PDT<o:p></o:p></span></p><div><p class=MsoNormal style='line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:black'>Last week we learned of a distinctly unusual case of advanced prostate cancer, and the patient has given us his permission to provide our readers with some specific information about his case. We do this both to offer information about the very different ways that prostate cancer can sometimes evolve, but also in case any […]<o:p></o:p></span></p></div></td></tr><tr><td style='padding:.75pt .75pt .75pt .75pt'><p style='mso-margin-top-alt:12.0pt;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:16.8pt'><a name=3></a><a href="http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/uhpjeGCFU2E/?utm_source=feedburner&utm_medium=email"><b><span style='font-size:13.5pt;font-family:"Arial","sans-serif";color:#000099;text-decoration:none'>Prediction of potentially lethal forms of prostate cancer</span></b></a> <o:p></o:p></p><p style='mso-margin-top-alt:6.75pt;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:#555555'>Posted: 05 Jul 2018 05:14 AM PDT<o:p></o:p></span></p><div><p class=MsoNormal style='line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:black'>An international, multi-institutional group of researchers appears to have been able to validate a new way to predict risk for aggressive forms of localized prostate cancer that have a high probability for progression to metastatic disease and prostate cancer-specific mortality. This new methodology is based on the methylation of specific pieces of DNA in a patient’s […]<o:p></o:p></span></p></div></td></tr></table><p class=MsoNormal style='line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:black;display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=1 cellpadding=0 width="100%" style='width:100.0%;border:none;border-top:solid #999999 1.0pt' id=footer><tr><td style='border:none;padding:3.0pt .75pt .75pt .75pt'><p class=MsoNormal style='mso-margin-top-alt:0cm;margin-right:4.5pt;margin-bottom:14.4pt;margin-left:0cm'><span style='font-size:8.5pt;font-family:"Helvetica","sans-serif";color:#333333'>You are subscribed to email updates from <a href="https://prostatecancerinfolink.net">THE "NEW" PROSTATE CANCER INFOLINK</a>..<o:p></o:p></span></p></td><td valign=top style='border:none;padding:3.0pt .75pt .75pt .75pt'><p class=MsoNormal align=right style='mso-margin-top-alt:0cm;margin-right:4.5pt;margin-bottom:14.4pt;margin-left:0cm;text-align:right'><span style='font-size:8.5pt;font-family:"Helvetica","sans-serif";color:#333333'>Email delivery powered by Google<o:p></o:p></span></p></td></tr><tr><td colspan=2 style='border:none;padding:3.0pt .75pt .75pt .75pt'><p class=MsoNormal style='mso-margin-top-alt:0cm;margin-right:4.5pt;margin-bottom:14.4pt;margin-left:0cm'><span style='font-size:8.5pt;font-family:"Helvetica","sans-serif";color:#333333'>Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States<o:p></o:p></span></p></td></tr></table><p class=MsoNormal><o:p> </o:p></p></div></div></body></html>